Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » ADAMTS13 and TTP

Abstract Number: PO156

A Refractory Thrombotic Thrombocytopenic Purpura Case Complicated by Hepatic Sinusoidal Obstruction Syndrome and Successful Management with Defibrotide

S. Erdem¹, M. Mastanzade¹, S. Altay-Dadin², M. Yanasik³, S. Kalayoglu-Besisik¹

Abstract Number: OC 53.4

Anti-ADAMTS13 Antibodies in Patients with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)

S.R. Heeb^1,2, M. Schaller^1,2, E. Tarasco^1,2, J.A. Kremer Hovinga^1,2

Abstract Number: OC 66.2

Anti-cysteine/Spacer Autoantibodies that Open the Conformation of ADAMTS13 Are a Common Feature of the Autoimmune Response in Immune-mediated Thrombotic Thrombocytopenic Purpura

L. De Waele¹, A. Curie^1,2, K. Kangro^1,3, E. Tellier⁴, G. Kaplanski^4,5, A. Männik³, C. Tersteeg¹, B.S. Joly⁶, P. Coppo⁷, A. Veyradier⁶, S.F. De Meyer¹, E. Roose¹, K. Vanhoorelbeke¹

Abstract Number: PB0838

Caplacizumab Rapidly Inhibits VWF-platelet Interaction: Pharmacodynamic Data from Healthy Volunteers and Patients with aTTP

F. Callewaert¹, J. Minkue Mi Edou², R. de Passos Sousa³

Abstract Number: OC 53.2

Children with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) Have a High Incidence of Acute Episodes: Data from the International Hereditary TTP Registry (IHTTP Registry)

E. Tarasco^1,2, K. Sakai³, S. Al Shanbary⁴, L. Bütikofer⁵, Y. El Chazli⁶, J.N George⁷, H. Hengartner⁸, S. Jalal⁹, P.N Knöbl¹⁰, E. Maaß¹¹, S. Milanovich¹², S. Perungo¹³, G. Sinkovits¹⁴, M. Steele¹⁵, A.S. von Krogh^16,17, K. Wyatt¹⁸, B. Lämmle^1,19, J.A. Kremer Hovinga^1,2, other members Steering Committee international hTTP Registry

Abstract Number: PB0850

Delayed Diagnosis of Congenital Thrombotic Thrombocytopenic Purpura Presenting as Recurrent Cryptogenic Strokes

M. Desancho¹, M. Beltrami Moreira¹

Abstract Number: PB0837

Design of a Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment with Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura

N. Jain¹, C. Marquez¹, L. Martell¹

Abstract Number: OC 66.4

Development of an Easy-to-Use ADAMTS13 Conformation Assay Using Fiber Optic Surface Plasmon Resonance Technology

C. Dekimpe¹, Q. Bonnez¹, E. Roose¹, E. Tellier², G. Kaplanski², H.B. Feys^3,4, C. Tersteeg¹, S.F. De Meyer¹, K. Vanhoorelbeke¹

Abstract Number: LPB0079

Evaluation of the Different Platelet-dependent von Willebrand Factor Activity Assays Capacity to Assess the in vivo Inhibitory Effect of Caplacizumab on the VWF-platelet Interaction

P. Colpani¹, L. Baronciani¹, C. Novembrino¹, I. Mancini², G. Cozzi¹, P. De Leo¹, E. Galbiati¹, M. Boscarino², A. Artoni¹, F. Peyvandi^1,2

Abstract Number: PB0845

Evaluation of the Local Tolerability of Recombinant ADAMTS13 Following Subcutaneous Injection in Rabbits

J. Blank¹, J. McNulty¹, J. Nunes¹

Abstract Number: PB0842

HIV is Not the Trigger for HIV-associated TTP

M. Meiring¹, M. Khemisi².

Abstract Number: OC 66.1

Investigating the Resistance of ADAMTS13 towards Protease Inhibitors

K. Singh^1,2, S. Sohrabipour^1,2, H. Madarati^1,2, T. Sparring^1,2, C. Kretz^1,2

Abstract Number: PB0844

Loss of Diagnostic Utility of D-dimers in Secondary Thrombotic Thrombocytopenic Purpura (TTP) in Patients with Human Immunodeficiency Virus (HIV) Infection

S. Louw¹, A. Mayne¹, E.S. Mayne¹

Abstract Number: PB0839

Low Plasma ADAMTS13 Activity Contributes to Increased Mortality Rate in Hospitalized Patients with Suspected Heparin-induced Thrombocytopenia

M. Chan¹, X.L. Zheng²

Abstract Number: OC 53.1

Major Adverse Cardiovascular Events Are a Major Cause of Morbidity after Recovery from Immune Thrombotic Thrombocytopenic Purpura

M. Brodsky¹, S. Selvakumar², L. Yanek¹, S. Hussain¹, A. Moliterno¹, R. Brodsky¹, S. Chaturvedi¹

Abstract Number: PB0836

Melanoma Triggers Severe Thrombotic Thrombocytopenic Purpura and Results in a High Mortality Rate in adamt13^-/- Zebrafish

L. Zheng¹, L. Cao², X.L. Zheng¹

Abstract Number: OC 53.3

Outcomes of Subsequent Pregnancy in Women with a History of Immune Thrombotic Thrombocytopenic Purpura

J. Brown¹, S. Hussain², M. Mazepa³, A. Moliterno², S. Chaturvedi²

Abstract Number: PB0851

PK/PD Modeling and Simulations Highlight the Importance of the Intravenous Loading Dose and Daily Dosing Regimen with Caplacizumab for Patients with aTTP

T. Sou¹, F. Callewaert², R. de Passos Sousa³, M.L. Sargentini-Maier¹

Abstract Number: PB0840

Plasma BioID of ADAMTS13

H. Madarati¹, K. Singh¹, T. Sparring¹, C. Kretz¹

Abstract Number: PO161

Refractory Thrombotic Thrombocytopenic Purpura – A Case Report

A. Aribandi¹, C. Ranjith¹, S. Sushma², T. Surapaneni²